Joanna Marta Bandola-Simon

Dr. Joanna Marta Bandola-Simon

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Molecular Immunology
Verified
Journal Article
Closed access
JBJoanna Marta Bandola-Simon
Joanna Marta Bandola-Simon
PRPaul A. Roche
Paul A. Roche

28 March 2013 in Blood
Verified
Journal Article
Open access
PDF file
STSebastian Thieme
Sebastian Thieme
TGTobias Gyárfás
Tobias Gyárfás
CRCornelia Richter
Cornelia Richter
Gunes OzhanGunes Ozhan
Gunes Ozhan
JFJun Fu
Jun Fu
SBSebastian Brenner
Sebastian Brenner
Key Points: UTX regulates migration and hematopoiesis. Female UTX-KO mice show key features of myelodysplastic syndrome with chromosomal instability.

1 March 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LLLei Lei
Lei Lei
JBJoanna Marta Bandola-Simon
Joanna Marta Bandola-Simon
PRPaul A. Roche
Paul A. Roche
March-I is a membrane-bound E3 ubiquitin ligase belonging to the membrane-associated RING-CH (March) family. March-I ubiquitinates and down-regulates expression of major histocompatibility complex (MHC) class II and cluster of differentiation 86 (CD86) in antigen presenting cells. March-I expression is regulated both transcriptionally and post-translationally and it has been reported that the March-I is ubiquitinated and that this ubiquitination contributes to March-I turnover. However, the molecular mechanism regulating March-I ubiquitination and the importance of March-I's E3 ligase activity for March-I ubiquitination are not fully understood. Here we confirmed that although March-I is ubiquitinated, it is not ubiquitinated on a lysine residue as a lysine-less March-I variant was ubiquitinated similarly to wild-type March-I. We found that March-I E3 ligase activity is not required for its ubiquitination and does not regulate March-I protein expression, suggesting that March-I does not undergo autoubiquitination. Knocking down ubiquitin-conjugating enzyme E2 D1 (Ube2D1) impaired March-I ubiquitination, increased March-I expression, and enhanced March-I-dependent downregulation of MHC class II proteins. Taken together, our results suggest that March-I undergoes lysine-independent ubiquitination by an as yet unidentified E3 ubiquitin ligase that together with Ube2D1 regulates March-I expression.

23 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CRCornelia Richter
Cornelia Richter
STSebastian Thieme
Sebastian Thieme
JBJoanna Marta Bandola-Simon
Joanna Marta Bandola-Simon
MLMagdalena Laugsch
Magdalena Laugsch
KAKonstantinos Anastassiadis
Konstantinos Anastassiadis
SBSebastian Brenner
Sebastian Brenner
Dendritic cells are the professional antigen presenting cells of innate immunity and key players in maintaining the balance of immune responses. Studies with dendritic cells are mainly limited by their low numbers in vivo and their difficult maintenance in vitro . We differentiated bone marrow cells from transgenic mice expressing an inducible SV40 large T-antigen into dendritic cells. When immortalized by dexamethasone and doxycycline, these cells were stable in long-term culture. In the absence of dexamethasone and doxycycline (de-induction), dendritic cells displayed properties of primary cells, characterized by expression of classical dendritic cell surface markers CD11c, CD11b, MHCII, CD40 and CD86. Furthermore, de-induced lipopolysaccharide activated dendritic cells secreted IL-1β, IL-6, TNFα and IL-12. De-induced, Ovalbumin-loaded dendritic cells polarize CD4 + T cells into Th1, Th17 and Th2 cells, indicating their correct antigen presenting property. Consistent with intratracheal application of Ovalbumin-loaded primary dendritic cells into mice, the application of de-induced dendritic cells resulted in recruitment of lymphocytes to the lungs. In summary, we successfully expanded dendritic cells using conditional immortalization. The generated dendritic cells demonstrate the characteristic immunophenotype of primary dendritic cells and will facilitate further studies on immunomodulatory properties of dendritic cells.

17 August 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JBJoanna Marta Bandola-Simon
Joanna Marta Bandola-Simon
CRCornelia Richter
Cornelia Richter
MRMartin Ryser
Martin Ryser
AJArshad Jamal
Arshad Jamal
MAMichelle P. Ashton
Michelle P. Ashton
STSebastian Thieme
Sebastian Thieme
Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotrophins and their receptors control the function of neuronal tissue. In addition, they have been demonstrated to be part of the immune response but little is known about the effector immune cells involved. We report, for the first time, the expression and immune-regulatory function of the low affinity neurotrophin receptor p75NTR by the antigen-presenting plasmacytoid dendritic cells (pDCs), mediated by Toll-like receptor (TLR) 9 activation and differential phosphorylation of interferon regulatory factor (IRF) 3 and 7. The modulation of p75NTR on pDCs significantly influences disease progression of asthma in an ovalbumin-induced mouse model mediated by the TLR9 signaling pathway. p75NTR activation of pDCs from patients with asthma increased allergen-specific T cell proliferation and cytokine secretion in NGF concentration dependent manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes in RIP-CD80GP mice and aggravated Graft-versus-Host disease in a xenotransplantation model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism connecting neurotrophin signaling and immune response regulation with great therapeutic potential for a variety of immune disorders.

17 April 2023 in Current Opinion in Immunology
Verified
Journal Article
Closed access
JBJoanna Marta Bandola-Simon
Joanna Marta Bandola-Simon
PRPaul A. Roche
Paul A. Roche